Kingdon Capital Management’s Haemonetics HAE Stock Holding History

Kingdon Capital Management’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-111,100	Closed	-$9.95M	–	87
2023 Q3	$9.95M	Buy	+111,100	New	+$9.92M	1.15%	36
2023 Q2	–	Sell	-50,000	Closed	-$4.14M	–	88
2023 Q1	$4.14M	Buy	+50,000	New	+$4.05M	0.78%	44
2022 Q3	–	Sell	-95,500	Closed	-$6.22M	–	77
2022 Q2	$6.22M	Buy	+95,500	New	+$5.65M	1.06%	32
2022 Q1	–	Sell	-135,000	Closed	-$7.16M	–	96
2021 Q4	$7.16M	Buy	135,000 +35,000	+35%	+$2.13M	0.82%	41
2021 Q3	$7.06M	Buy	+100,000	New	+$6.31M	0.86%	35

Other funds holding HAE

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Kingdon Capital Management's HAE Position: Q4 2023 in Review

Kingdon Capital Management sold out of Haemonetics (HAE) in Q4 2023, closing a stake of 111,100 shares — an estimated $9.95M sold.

Kingdon Capital Management first reported a position in HAE in Q3 2021 and held it in 5 quarters. The position peaked at $9.95M in Q3 2023. 295 funds tracked by Wall St. Rank hold HAE as of Q4 2023.

Kingdon Capital Management reported no remaining Haemonetics position as of Q4 2023 after selling out during the quarter.
Kingdon Capital Management sold 111,100 Haemonetics shares in Q4 2023, an estimated $9.95M.
Kingdon Capital Management first reported a position in Haemonetics in Q3 2021 and held it in 5 quarters.
Kingdon Capital Management's Haemonetics position peaked at $9.95M in Q3 2023.
295 funds tracked by Wall St. Rank held Haemonetics as of Q4 2023.

Based on Kingdon Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.